医保商会日前发布关于去年中国医药进出口情况数据：2012年，我国医药产品进出口总值809.5亿美元，增幅10.5%，再创历史新高。其中，出口476.0亿美元，同比增6.9%；进口333.5亿美元，同比增15.9%，对外贸易顺差142.5亿美元，同比减少9.5%。

Medical insurance chamber of commerce released last year for Chinese medicine import and export data:In 2012,,Our country medicine products import and export (GDP) of us $80.95 billion,10.5%,Hit a record high.the,Export $47.6 billion,Increased by 6.9% year-on-year;Imported 33.35 billion us dollars,Increased by 15.9% year-on-year,Foreign trade surplus of $14.25 billion,Reduced by 9.5% year-on-year.

　　据了解，三大类出口商品中，西药类、医疗器械类产品出口额分别为275.2亿美元和175.9亿美元，总出口占比高达94.8%。

It is understood,Three types of export commodities,Western medicine class/Medical equipment products export $27.52 billion and $17.59 billion, respectively,Total exports accounted for more than 94.8%.

　　其中，一个值得关注的动向是：我国医药企业正加快国际注册认证进程。据医保商会副会长许铭介绍，2012年，我国医药企业向美国食品药品管理局（FDA）提交申请总数达到1259份；向欧洲药品质量管理局（EDQM）提交CEP（原料药注册审评）申请173份，较2011年同比增长34.1%，有效证书总数达到393份。

the,A notable trend is:The medicine enterprises in our country is to speed up the international registration of the authentication process.According to the medical insurance, vice chairman of the chamber of commerce XuMing is introduced,In 2012,,The medicine enterprises in our country to the United States food and drug administration(FDA)Submit the application for a total of 1259 copies;To Europe for the quality of medicines(EDQM)Submit CEP(Registered drug evaluation)Application of 173,A year-on-year growth of 34.1% in 2011,Valid certificate for a total of 393 copies.

　　此外，制剂出口也迎来发展拐点。据协会统计，长期以来，西药制剂一直不是主力出口产品。但在2012年，西药制剂出口高速增长，出口额增幅高达17.9%，表现出强劲的发展势头。

In addition,Preparation exports also welcome the development of inflection point.According to the association,For a long time,Western medicine preparation has not been main export products.But in 2012,Western medicine preparation export growth,Export growth of 17.9%,Show a strong momentum of development.

　　如华海药业，在2007年就制定了进军海外的发展战略，到2012年终于进入收获期。华海药业的2012年业绩预告显示，公司制剂外销快速增长，预计比上年同期增长约200%。长江证券最新研报也预计，2013年公司制剂出口业务的增速仍将超过100%，高增速还将保持2至3年。

Such as huahai pharmaceutical,In 2007 established the overseas development strategy,By 2012 finally entered the harvest time.Huahai pharmaceutical 2012 earnings forecast shows,The company preparation export rapid growth,Is expected to increase about 200% over the same period of last year.The Yangtze river securities latest research report also expected,In 2013 the company preparation export growth will be more than 100%,High growth will remain 2 to 3 years.

　　可以说，加快海外出口战略也是浙江原料药上市公司的重要抓手。浙江永太科技股份的相关人士透露，在2011年之前，医药板块部分的出口和内销持平；到2012年出口业务的比重已经上升到85%，公司已在美国投资设立了子公司，未来在相关产品获得美国FDA的认证后，将有望在美国开展生产销售。

Can say,To speed up the overseas export strategy is zhejiang API listed company important gripper.Zhejiang ever too technology shares relevant sources,In the 2011 years ago,Medicine plate part of the export and domestic flat;By 2012 the proportion of export business has risen to 85%,The company has invested in a subsidiary in the United States,In the future related products for the FDA's authentication,In the United States are expected to carry out the production sales.